Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
Luca Potestio, Ilaria Piscitelli, Gabriella Fabbrocini, Fabrizio Martora, Angelo Ruggiero,* Matteo Megna* Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy*These authors contributed equally to this workCorresp...
Saved in:
Main Authors: | Potestio L (Author), Piscitelli I (Author), Fabbrocini G (Author), Martora F (Author), Ruggiero A (Author), Megna M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022) -
Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
by: Megna M, et al.
Published: (2024) -
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
by: Potestio L, et al.
Published: (2023) -
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
by: Martora F, et al.
Published: (2023) -
Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
by: Potestio L, et al.
Published: (2023)